http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20180019089-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f2dba04112d75b8e228aba17db57f3b0 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-736 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7004 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-702 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-702 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7004 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-736 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 |
| filingDate | 2016-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f9f401178087ef0dabf3024d84f50dc |
| publicationDate | 2018-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20180019089-A |
| titleOfInvention | Compositions and methods for inhibiting amylase-mediated hydrolysis of alpha (1 to 4) -linked glucose polymers |
| abstract | PAZ320 is a mixture of two galactomannans (GMa and GMPβ), which is being developed to treat diabetes and inflammatory diseases. GMα and GMβ both have a β (1 → 4) backbone with a high density of α (1 → 6) linked galactose units. When ingested by diabetics, PAZ320 reduces the magnitude of postprandial glucose fluctuations. PAZ320 binds to the enzyme hydrolyzing starch in the gastrointestinal tract, thereby reducing the steady-state concentration of low molecular weight sugars such as glucose. PAZ320 attenuates the rate of amylase-mediated hydrolysis of α (1 → 4) -bonded glucose polymers (starch and maltohexaose) by binding to α-amylase enzymes from human and pig sources. We have found that PAZ 320 at 2.5 mg / ml inhibits amylase activity with starch to about 45%, which is an inhibition level comparable to that of acarbose at 0.13 mg / ml. Furthermore, the present inventors have found that the GM alpha component of PAZ320 is about 5-fold more active than GM beta. Both GMs also "unfold" the coiled structure of the starch without affecting the inhibitory effect on amylase. On the other hand, some of the inhibitory effect from GMa in vitro arises from its effect on solution viscosity increase. |
| priorityDate | 2015-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 120.